VivoSim Reports First Commercial Sales in China for NAMkind Testing Services
VivoSim (NASDAQ:VIVS) announced its first commercial sales in mainland China through two paid testing programs secured by its local distributor, Tekon. The engagements involve a Shanghai-based oncology biotech company and a pharmaceutical company in Chengdu, covering gastrointestinal toxicology screening and efficacy profiling for drug candidates in oncology and other disease areas. Management stated these contracts represent a meaningful portion of the company's contracted revenue to date and establish a commercial presence in the Chinese market. The addressable Chinese market for liver and gastrointestinal in vitro models and toxicology services is estimated at approximately $2 billion with 10% annual growth. The company's entry into China expands its geographic reach beyond the U.S. and Europe, aligning with industry trends favoring non-animal testing methodologies. Investors will watch for additional contracts and broader adoption across the Asia-Pacific region.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection